If we could get more platforms in place where you could just go right into a particular disease without having to recontract and redo everything, you could generate the data a lot faster. Those kind of networks need to get scaled if the US wants to remain competitive.
a16z Podcast · Novartis CEO Vasant Narasimhan on Transforming a...“all of the stuff that can really slow down your ability to get a trial started up in The US.”
all of the stuff that can really slow down your ability to get a trial started up in The US. Mhmm. If we could get more platforms in place where you could just, you know, go right in in a particular disease without having to recontract and redo everything, I think you could generate the data a lot faster. And I think those kind of networks now need to get scaled if if The US wants to remain competitive.
Why this clip
Identifies a specific bottleneck (contracting/IRB reviews) that slows US drug development and connects it to national competitiveness. Practical insight into regulatory reform with clear competitive implications.
More from this guest
Vasant Narasimhan
1 appearance · 6 clips
More from this episode
From the blog
Want clips like this for your podcast?
We find your top 5-8 clips, write the hooks, and deliver ready-to-post content. First 2 episodes are free.
Get 2 Episodes Clipped Free